Resmetirom, a selective liver thyroid hormone receptor (THR-) agonist, received approval from the FDA in 2024 for the treatment of adult patients with F2-F3 MASH (4)
Cognitive behavioral therapy has evidence supporting its use in chronic pain conditions including allodynia
The combination may significantly amplify these symptoms, potentially leading to dehydration, electrolyte imbalances, and reduced medication adherence
Because youre not doing anyone a favor, you may be causing more harm than good. If youre having side effects from GLP-1 or similar drugs, whether youre taking Ozempic, Wegovy, or Mounjaro, a physician can order tests to identify whether the medication is the problem
As demand for GLP-1 therapies continues to expand, programs that prioritize structure and accountability are increasingly relevant
Choose an injection site